Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study in Second Line Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2010-08-18
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1072
- Registration Number
- NCT01183780
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan
A Study of Tadalafil in Benign Prostatic Hyperplasia
- First Posted Date
- 2010-08-17
- Last Posted Date
- 2012-05-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT01183650
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munich, Germany
A Study in Participants With Diabetic Peripheral Neuropathic Pain in China
- First Posted Date
- 2010-08-11
- Last Posted Date
- 2014-10-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 405
- Registration Number
- NCT01179672
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yueyang, China
An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults
- First Posted Date
- 2010-08-09
- Last Posted Date
- 2012-02-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 26
- Registration Number
- NCT01178099
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, UK, United Kingdom
A Bioequivalence (BE) Study in Healthy Subjects
- First Posted Date
- 2010-08-09
- Last Posted Date
- 2011-10-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 42
- Registration Number
- NCT01177943
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan
A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-08-05
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 402
- Registration Number
- NCT01175811
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yong Kung City, Taiwan
Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-08-05
- Last Posted Date
- 2014-02-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 478
- Registration Number
- NCT01175824
- Locations
- 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Istanbul, Turkey
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2010-08-02
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1416
- Registration Number
- NCT01173601
- Locations
- 🇺🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vinnytsya, Ukraine
A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2010-07-27
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 665
- Registration Number
- NCT01170663
- Locations
- 🇬🇧
ImClone Investigational Site, Wolverhampton, West Midlands, United Kingdom
A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2010-07-23
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1253
- Registration Number
- NCT01168973
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wolverhampton, West Midlands, United Kingdom